OMER Новости Форекс
Omeros Says FDA Grants Orphan Drug Designation To MASP-3 Inhibitor OMS906
Omeros Corp (OMER) announced Friday that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
RTTNews
|
895 дней спустя
